The Latest Breaking News from PTC

The U.S. Food and Drug Administration approved on Monday PTC Therapeutics, Inc.’s (NASDAQ:PTCT) SEPHIENCE (sepiapterin) for children and adult patients with phenylketonuria (PKU).

Autodesk stock on Monday rebounded from a sharp sell-off after the design software firm ruled out a potential bid for industry peer PTC.

PTC has underperformed the broader market over the past year, yet analysts remain moderately optimistic about the stock’s prospects.

PTC is prepared to release its second-quarter results later this month, with analysts predicting a single-digit earnings drop.

Despite PTC Inc.’s recent underperformance relative to its broader sector, analysts remain highly optimistic about the stock’s prospects.

Although PTC has underperformed the broader market over the past year, analysts remain highly optimistic about its future potential.

As the robotics field progresses and enters more industries, robotics stocks are becoming increasingly promising investments. With AI-driven advancements accelerating growth, now could be an opportune time to tap into this booming sector with fundamentally sound stocks like PTC Inc. (PTC), UiPath (PATH), and FARO Technologies (FARO). Read more….

PTC is scheduled to release its fiscal first-quarter earnings by the end of this month, and analysts anticipate a decline in its EPS by lower-double digits.

Innovative solutions are revolutionizing sectors around the globe and bringing in a new industrial revolution. In this thriving landscape, should PTC Inc. (PTC), with its industry-leading software offerings, be on your radar? Read on….